FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 336:1674-1675 June 5, 1997 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Alberts, D. S.

To the Editor: In their report on intraperitoneal versus intravenous cisplatin for stage III ovarian cancer, Alberts et al. (Dec. 26 issue)¹ suggest that among the patients with microscopical disease (no gross residual disease), the rates of complete pathological responses differed in the intravenous and intraperitoneal groups (complete-response rate, 56 and 80 percent, respectively) because "the penetration of intraperitoneal cisplatin is limited to a depth of 0.1 to 1 mm from the surface of the peritoneal tumor," and they cite a report by Los et al.² However, there were no significant differences in survival between this subgroup of patients and . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.